Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: July 24, 2011
Last updated: February 20, 2014
Last verified: February 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)